Baidu
map

政策与人文

订阅

MedSci主页 / 所有栏目 / 政策与人文

医药代表的7大特长，看完都是泪

2018-01-31 佚名 医药招聘

医药代表特长
关注

医药代表与一般销售的七大区别！

区别一：起床方式

一般销售：一般早上8点起床，最迟9点就位，没准还要跳上半个小时的洗脑广场销售舞（今天我最棒，棒棒棒棒）。

医药代表：看情况，0点—24:00不确定！

区别二：销售模式

一般销售：买买买！我的产品就是好，快掏钱！

医药代表：卖乖、卖萌、卖自己（别想歪）

区别三：工作时间

一般销售：朝九晚五，偶尔加班

医药代表：别跟我说下班！等会儿还要夜访。

区别四： 别人眼里

一般销售：潜力股，社会精英

医药代表：钱多？神秘？…………

区别五：行业前景

一般销售：升职加薪当上总经理出任ceo赢取白富美。

医药代表：各种合规，不被裁员已经算幸运了！

区别六：各自的客户

一般销售：王总，李科长，张大妈，赵阿姨……

医药代表：王老师，李老师，张老师，赵老师……

区别七：周末时光

一般销售：看电影，陪女朋友，爬山，睡觉。

医药代表：城市会，学术会，沙龙，各种会。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1666680, encodeId=8549166668082, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Nov 30 16:29:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409329, encodeId=fa631409329a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443590, encodeId=0eb71443590fa, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284323, encodeId=054b284323ff, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Feb 02 05:01:06 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283962, encodeId=c445283962a6, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Wed Jan 31 22:08:15 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283919, encodeId=b8b4283919bb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 31 20:02:46 CST 2018, time=2018-01-31, status=1, ipAttribution=)]
    2018-11-30 fengyqf

    #药代#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1666680, encodeId=8549166668082, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Nov 30 16:29:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409329, encodeId=fa631409329a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443590, encodeId=0eb71443590fa, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284323, encodeId=054b284323ff, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Feb 02 05:01:06 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283962, encodeId=c445283962a6, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Wed Jan 31 22:08:15 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283919, encodeId=b8b4283919bb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 31 20:02:46 CST 2018, time=2018-01-31, status=1, ipAttribution=)]
    2018-02-02 hb2008ye

    #医药#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1666680, encodeId=8549166668082, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Nov 30 16:29:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409329, encodeId=fa631409329a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443590, encodeId=0eb71443590fa, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284323, encodeId=054b284323ff, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Feb 02 05:01:06 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283962, encodeId=c445283962a6, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Wed Jan 31 22:08:15 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283919, encodeId=b8b4283919bb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 31 20:02:46 CST 2018, time=2018-01-31, status=1, ipAttribution=)]
    2018-02-02 ms9203727104890838

    #医药代表#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1666680, encodeId=8549166668082, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Nov 30 16:29:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409329, encodeId=fa631409329a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443590, encodeId=0eb71443590fa, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284323, encodeId=054b284323ff, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Feb 02 05:01:06 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283962, encodeId=c445283962a6, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Wed Jan 31 22:08:15 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283919, encodeId=b8b4283919bb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 31 20:02:46 CST 2018, time=2018-01-31, status=1, ipAttribution=)]
    2018-02-02 三生有幸9135

    学习一下谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1666680, encodeId=8549166668082, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Nov 30 16:29:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409329, encodeId=fa631409329a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443590, encodeId=0eb71443590fa, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284323, encodeId=054b284323ff, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Feb 02 05:01:06 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283962, encodeId=c445283962a6, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Wed Jan 31 22:08:15 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283919, encodeId=b8b4283919bb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 31 20:02:46 CST 2018, time=2018-01-31, status=1, ipAttribution=)]
    2018-01-31 1e0e5a1fm42(暂无匿称)

    henhao

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1666680, encodeId=8549166668082, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Fri Nov 30 16:29:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409329, encodeId=fa631409329a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443590, encodeId=0eb71443590fa, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUnmV4MWxxicaHm4w2E4EPicofrVHWChQPKibnOtt8t8j7jYGkdKxNvF0KkC2sDXw04QS2GS2UUBSLg/132, createdBy=5cc15086507, createdName=ms9203727104890838, createdTime=Fri Feb 02 08:29:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284323, encodeId=054b284323ff, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Feb 02 05:01:06 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283962, encodeId=c445283962a6, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Wed Jan 31 22:08:15 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283919, encodeId=b8b4283919bb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 31 20:02:46 CST 2018, time=2018-01-31, status=1, ipAttribution=)]
    2018-01-31 Y—xianghai

    学习了新知识

    0

相关资讯

发改委发文，医药人睡不着了！

医用耗材加成要取消！有人欢喜有人愁，医院愁、医药人也愁！医院捂心肝微微冷笑，吓得医药人如钢箭穿身，剧痛。 ▍发改委：医用耗材加成要取消 11月10日，国家发改委发布《关于全面深化价格机制改革的意见》。顾名思义，这个文件说的是钱的事。听闻发改委要“进一步取消医用耗材加成”，特向医药人禀报。在文件第四部分的“加快完善公用事业和公共服务价格机制”中，发改委提出要巩固取消药品加成成果，

备案制下的百万药代还有这些新出路（上篇）

从今年2月9日国务院办公厅印发《关于进一步改革完善药品生产流通使用政策的若干意见》中首先从国家层面提出要求医药代表只能从事学术推广、技术咨询等活动，不得承担药品销售任务，其失信行为记入个人信用记录的代表备案制,到上海出台的代表备案中的“三定一有”及安徽相继出台医药代表备案细则，再到十九大明确提出全面以药养医,《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》中再次重申禁止医药代表承担药品销售任

国家版药代备案制征求意见 医药代表行为法制化

果然又是周五见！CFDA真是拼了，在这个时候，医药代表登记备案管理办法（征求意见稿）正式出炉……2017年12月22日晚7时许，国家食品药品监督管理总局以及国家卫计委同时在官方网站挂出消息，就“医药代表登记备案管理办法”（以下简称“办法”）正式面向社会公开征求意见，共计五大章节二十条内容。备受关注的医药代表登记备案管理办法终于“千呼万唤始出来”。可以说，从年初至岁末，自2017年重磅政策文件《

医药代表从业新规征求意见：医药代表不得承担药品销售任务

国家食品药品监督管理总局和国家卫生计生委日前发布《医药代表登记备案管理办法（试行）（征求意见稿）》，向社会公开征求意见。意见稿提出，医药代表不得承担药品销售任务，不得参与统计医生个人开具的药品处方数量，不得直接销售实物药品，不得收款和处理购销票据，不得进行商业贿赂。

Baidu
map
Baidu
map
Baidu
map